About
Dr. Hongping Yu has worked in drug discovery and development in large pharmaceutical companies for over 15 years. He has successfully delivered more than a dozen of preclinical candidates across a wide range of therapeutic areas with many advanced into clinical development. Prior to co-founding Abbisko, Dr. Yu served as the first head of chemistry at Hansoh Pharmaceutical Company, built up the chemistry team, and led the discovery of multiple drug candidates including next generation inhibitors of EGFR, FXR, NS5A/B and others. In previous positions, Dr. Yu worked as senior investigator at Novartis and research chemists at Merck. Dr. Yu obtained his Ph.D. in organic chemistry from the University of British Columbia and B.S. & M.S. from Tsinghua University. He is a member of the China “Thousand Talent Program”.
Position in the VCSift Database
- • 3 investors at Abbisko Therapeutics are tracked.
- • 2 investors hold the Sr. VP role in VCSift. Hongping Yu is one of them.
- • 110 investors are based in China.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- China
Contact Information
Find more investors like Hongping
Search Investors